GlassScriptPhysician profile
Karen Lynette Williams
NPI 1598154650
$6,776.21
in general payments reported to CMS, 2019-2025
47 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,529 · 2022: $2,746 · 2023: $699 · 2024: $434 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.85 | 2021-2024 | |
| Lilly USA, LLC | $552.53 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $529.58 | 2021-2025 | Wegovy |
| Amgen INC. | $424.44 | 2021-2024 | Repatha, Otezla, Prolia |
| Bausch Health US, LLC | $350.52 | 2021-2025 | Aplenzin |
| Esperion Therapeutics, INC. | $299.80 | 2021-2022 | |
| Amarin Pharma, INC. | $293.60 | 2021-2022 | |
| Allergan, INC. | $274.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $259.79 | 2021-2025 | Farxiga |
| Glaxosmithkline, LLC. | $223.83 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $205.75 | 2021 | |
| Antares Pharma, INC. | $195.28 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $189.61 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $180.82 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $135.63 | 2021-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.